<DOC>
	<DOCNO>NCT01610791</DOCNO>
	<brief_summary>This open label , single arm study assess safety efficacy RoActemra/Actemra ( tocilizumab ) patient moderate severe active rheumatoid arthritis inadequate response disease-modifying antirheumatic drug ( DMARDs ) . Patients receive RoActemra/Actemra dose 8 mg/kg intravenously every 4 week 24 week ( 6 infusion ) .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Patients With Active Rheumatoid Arthritis Who Have Inadequate Response DMARDs ( REMISSION )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe active rheumatoid arthritis ( DAS28 &gt; 3.2 screening ) Inadequate response DMARDs Body weight &lt; 150 kg Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month enrollment Rheumatic autoimmune disease RA American College Rheumatology ( ACR ) functional class IV Prior history current inflammatory joint disease RA Previous treatment biologic drug use treatment RA Intraarticular parenteral corticosteroid within 6 week prior baseline Pregnant lactate woman Active current history recurrent infection , active TB within previous 3 year , HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>